BB Biotech AG reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was CHF 0.723 million compared to CHF 235.77 million a year ago. Net loss was CHF 299.86 million compared to net income of CHF 220.95 million a year ago. Basic loss per share from continuing operations was CHF 5.43 compared to basic earnings per share from continuing operations of CHF 3.99 a year ago. Diluted loss per share from continuing operations was CHF 5.43 compared to diluted earnings per share from continuing operations of CHF 3.99 a year ago.